Systematic review: colitis associated with anti-CTLA-4 therapy. (Q38529051)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

review article

1 reference

title

Systematic review: colitis associated with anti-CTLA-4 therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

A Gupta

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

K M De Felice

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

S Khanna

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

English

0 references

publication date

15 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

406-417

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

17 February 2020

cites work

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

21 January 2018

1 reference

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

21 January 2018

1 reference

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

21 January 2018

1 reference

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

Colonic toxicity of administered drugs and chemicals.

21 January 2018

1 reference

Drug-induced inflammatory bowel disease and IBD-like conditions.

21 January 2018

1 reference

Colitis associated with biological agents

21 January 2018

1 reference

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

21 January 2018

1 reference

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.

21 January 2018

1 reference

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody

21 January 2018

1 reference

21 January 2018

1 reference

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

21 January 2018

1 reference

Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease.

21 January 2018

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

21 January 2018

1 reference

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events

21 January 2018

1 reference

Lymphocytic colitis secondary to ipilimumab treatment.

21 January 2018

1 reference

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

Ipilimumab-induced perforating colitis

21 January 2018

1 reference

Ipilimumab-associated colitis: CT findings

21 January 2018

1 reference

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

21 January 2018

1 reference

Ipilimumab-induced acute severe colitis treated by infliximab.

21 January 2018

1 reference

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

21 January 2018

1 reference

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

Ipilimumab-induced colonic perforation

21 January 2018

1 reference

Steroid-induced sigmoid diverticular perforation in a patient with temporal arteritis: a rare clinical pathology

21 January 2018

1 reference

Abatacept for Crohn's disease and ulcerative colitis

21 January 2018

1 reference

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

21 January 2018

1 reference

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis?

21 January 2018

1 reference

CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: a meta-analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.13281

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26079306%20AND%20SRC:MED&resulttype=core&format=json

release_rxnw3oiqszgd3jguqblhrhobxq

17 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rxnw3oiqszgd3jguqblhrhobxq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference